With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP1 receptor agonists Read More
We compared the use of GLP-1RAs with second- or third-line glucose-lowering therapy to minimise confounding [22], thereby allowing us to explore the impact of including a reference group with the same disease stage, even though we adjusted for microvascular complications
First, A Quick Refresher on BPC-157 Before we dive into injection sites, it's crucial to understand why BPC-157 is even in this conversation
First, you must have completed at least 5 to 6 weeks of daily dosing
doi: 10.1158/1055-9965.EPI-18-1300 305
This reaction may serve two important functions in alleviating hepatic steatosis: firstly, the bioactivation of medium-chain fatty acids for -oxidation, and secondly, the production of hexanoyl-CoA and octanoyl-CoA, which inhibit the transcription of lipogenesis genes, such as ACACA and FASN [61]
)
